CA2567803A1 - Injectable pharmaceutical suspension comprising posaconazole - Google Patents

Injectable pharmaceutical suspension comprising posaconazole Download PDF

Info

Publication number
CA2567803A1
CA2567803A1 CA002567803A CA2567803A CA2567803A1 CA 2567803 A1 CA2567803 A1 CA 2567803A1 CA 002567803 A CA002567803 A CA 002567803A CA 2567803 A CA2567803 A CA 2567803A CA 2567803 A1 CA2567803 A1 CA 2567803A1
Authority
CA
Canada
Prior art keywords
formulation
posaconazole
mean
plasma
hour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002567803A
Other languages
English (en)
French (fr)
Inventor
Leonore Witchey-Lakshmanan
Sydney Ugwu
Varda Sandweiss
Catherine Hardalo
Roberta S. Hare
Gopal Krishna
Zaiqi Wang
Marco Taglietti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2567803(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2567803A1 publication Critical patent/CA2567803A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002567803A 2004-05-28 2005-05-27 Injectable pharmaceutical suspension comprising posaconazole Abandoned CA2567803A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57512604P 2004-05-28 2004-05-28
US60/575,126 2004-05-28
PCT/US2005/018945 WO2005117831A1 (en) 2004-05-28 2005-05-27 Injectable pharmaceutical suspension comprising posaconazole

Publications (1)

Publication Number Publication Date
CA2567803A1 true CA2567803A1 (en) 2005-12-15

Family

ID=34971355

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002567803A Abandoned CA2567803A1 (en) 2004-05-28 2005-05-27 Injectable pharmaceutical suspension comprising posaconazole

Country Status (15)

Country Link
EP (1) EP1761247A1 (enExample)
JP (1) JP2008501034A (enExample)
KR (1) KR20070027564A (enExample)
CN (1) CN1988887A (enExample)
AR (1) AR049063A1 (enExample)
AU (1) AU2005249502A1 (enExample)
CA (1) CA2567803A1 (enExample)
IL (1) IL179627A0 (enExample)
MX (1) MXPA06013886A (enExample)
NO (1) NO20066005L (enExample)
PE (1) PE20060291A1 (enExample)
RU (1) RU2006146555A (enExample)
TW (1) TWI290051B (enExample)
WO (1) WO2005117831A1 (enExample)
ZA (1) ZA200609890B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018182562A1 (en) * 2017-03-26 2018-10-04 Stafford Vivi Robyn Method of treatment of skin conditions of eye lids

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009469A1 (en) * 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
RS56044B1 (sr) * 2006-05-12 2017-09-29 Christian Noe Primena kombinovanih preparata koji sadrže antimikotike
EP2130540A1 (en) 2008-06-02 2009-12-09 Sandoz AG Pharmaceutical compositions containing a crystalline form of posaconazole
EP2141159A1 (en) 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
EP2451805A1 (en) 2009-07-09 2012-05-16 Sandoz AG A crystalline form of posaconazole
WO2011144656A1 (en) 2010-05-19 2011-11-24 Sandoz Ag Preparation of posaconazole intermediates
WO2011144655A1 (en) 2010-05-19 2011-11-24 Sandoz Ag Process for the preparation of chiral hydrazides
CA2798010C (en) 2010-05-19 2018-09-25 Sandoz Ag Purification of posaconazole and of posaconazole intermediates
RU2585760C2 (ru) 2010-05-19 2016-06-10 Сандоз Аг Способ получения хиральных триазолонов
EP3391890B1 (en) * 2010-06-29 2021-08-25 Merck Sharp & Dohme Corp. Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
CN108329303A (zh) 2011-06-16 2018-07-27 桑多斯股份公司 制备手性化合物的方法
CN103284959B (zh) * 2012-02-22 2015-06-03 重庆圣华曦药业股份有限公司 泊沙康唑冻干粉针剂及制备方法
CN102755628B (zh) * 2012-07-16 2013-10-23 中国科学院微生物研究所 一种抗真菌的药物组合物
CN102805731B (zh) * 2012-08-22 2014-04-30 北京莱瑞森医药科技有限公司 泊沙康唑干混悬剂及其制备方法
CN105030668B (zh) * 2015-06-26 2018-03-27 济川药业集团有限公司 泊沙康唑口服混悬剂及其制备方法
CN106333925B (zh) * 2015-07-10 2019-06-18 上海美悦生物科技发展有限公司 一种泊沙康唑液体混悬剂及其制备方法
CN105997872B (zh) * 2016-07-08 2019-02-19 河南省立眼科医院 一种含有泊沙康唑的眼用纳米胶束抗真菌溶液
CA3063115A1 (en) * 2017-04-12 2018-10-18 Vikash J. BHAGWANDIN Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors
CN110507609B (zh) * 2018-05-21 2021-09-17 上海医药工业研究院 泊沙康唑口服混悬剂的制备方法
CN111514146A (zh) * 2020-04-28 2020-08-11 山西振东泰盛制药有限公司 含有泊沙康唑的药物组合物
CN113933131B (zh) * 2021-09-24 2024-01-26 合肥天一生物技术研究所有限责任公司 一种阴道微生物荧光染色液

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
EP2090165A3 (en) * 2001-04-03 2012-03-28 Schering Corporation Antifungal composition with enhanced bioavailability

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018182562A1 (en) * 2017-03-26 2018-10-04 Stafford Vivi Robyn Method of treatment of skin conditions of eye lids

Also Published As

Publication number Publication date
NO20066005L (no) 2007-02-27
EP1761247A1 (en) 2007-03-14
TWI290051B (en) 2007-11-21
RU2006146555A (ru) 2008-07-20
WO2005117831A1 (en) 2005-12-15
AR049063A1 (es) 2006-06-21
ZA200609890B (en) 2008-09-25
KR20070027564A (ko) 2007-03-09
PE20060291A1 (es) 2006-04-14
CN1988887A (zh) 2007-06-27
JP2008501034A (ja) 2008-01-17
TW200609001A (en) 2006-03-16
AU2005249502A1 (en) 2005-12-15
IL179627A0 (en) 2007-05-15
MXPA06013886A (es) 2007-01-26

Similar Documents

Publication Publication Date Title
US20090226527A1 (en) Particulate-stabilized injectable pharmacutical compositions of posaconazole
CA2567803A1 (en) Injectable pharmaceutical suspension comprising posaconazole
KR102284689B1 (ko) 동결건조된 리포좀
CN107260679B (zh) 用以减少眼用类固醇的并发症的药物组合物
RU2618456C2 (ru) Фармацевтические препараты азолов для парентерального введения и способы их получения и применения для лечения заболеваний, чувствительных к азольным соединениям
US11197909B2 (en) Compositions and methods for the treatment of fungal infections
US20060009469A1 (en) Particulate-stabilized injectable pharmacutical compositions of posaconazole
US20190105268A1 (en) Viscoelastic Gel of Liraglutide Adapted for Once-Weekly or Once Bi-Weekly Administration
TW202005652A (zh) 醫藥配方
US11260028B2 (en) Nanosome formulations of aprepitant and methods and applications thereof
TW202024058A (zh) 用於治療真菌感染之化合物及方法
KR20200135280A (ko) 지속 방출 펩티드 제형
US20250082574A1 (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
HK40090116A (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
HK40040387A (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
HK40040387B (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
HK1242192A1 (en) Pharmaceutical compositions to reduce complications of ocular steroid
HK1201723B (en) Pharmaceutical compositions to reduce complications of ocular steroid

Legal Events

Date Code Title Description
FZDE Discontinued